Study Summary
This trial is to test the possible benefits and side effects of platelet-rich plasma for treating menopause symptoms in breast cancer patients. Platelet-rich plasma is made by taking 4-6 tablespoons of blood from a patient's arm and spinning it in a centrifuge to separate the plasma and red blood cells. The platelet-rich plasma is then injected into the patient.
- Genitourinary Syndrome of Menopause
- Breast Cancer
- Female Genitourinary Infection
- Menopause
- Stage 1 Breast Cancer
- Stage IA Breast Cancer
- Stage II Breast Cancer
- Stage IIA Breast Cancer
- Stage III Breast Cancer
- Prognostic Stage 0 Breast Cancer
- Stage 2 Breast Cancer
- Stage IIB Breast Cancer
- Stage IIIA Breast Cancer
- Stage IIIB Breast Cancer
- Stage 0 Breast Cancer
- Stage IB Breast Cancer
Treatment Effectiveness
Effectiveness Progress
Study Objectives
4 Primary · 13 Secondary · Reporting Duration: 2 years
Trial Safety
Safety Progress
Side Effects for
Trial Design
2 Treatment Groups
Treatment Group
1 of 2
Treatment of GSM (platelet rich plasma)
1 of 2
Experimental Treatment
20 Total Participants · 2 Treatment Groups
Primary Treatment: PRP · No Placebo Group · Phase 1
Trial Logistics
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age 18+ · Female Participants · 8 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Who else is applying?
What state do they live in?
Pennsylvania | 100.0% |
How old are they?
65+ | 100.0% |
What site did they apply to?
Mayo Clinic in Florida | 100.0% |
What portion of applicants met pre-screening criteria?
Met criteria | 100.0% |
How responsive is this trial?
Typically responds via
100.0% | |
Frequently Asked Questions
Has the Food and Drug Administration authorized platelet-rich plasma for medical use?
"With limited prior evidence of efficacy and safety, PRP was assigned a 1 on our team's scale." - Anonymous Online Contributor
What is the ultimate ambition of this clinical experiment?
"This long-term trial is intended to evaluate the amount of adverse events caused by treatment, as well as changes from baseline in Vaginal and Vulvar Assessment Scale (VAS/VuAS), Vaginal Maturation Index (VMI) and Day-to-Day Impact of Vaginal Aging Questionnaire (DIVA). This assessment will span two years." - Anonymous Online Contributor
Could you please provide an approximate figure of how many participants are involved in the experiment?
"Affirmative. The clinicaltrials.gov database points to this experiment still actively seeking recruits, which began on September 23rd 2020 and was most recently updated November 9th 2022. A total of 20 people are needed from one location for the trial's completion." - Anonymous Online Contributor
Are there any remaining vacancies for test subjects in this research endeavor?
"Affirmative. The trial data on clinicialtrials.gov confirms that the medical study, which was first published on September 23rd 2020 is currently recruiting participants. Twenty patients need to be enrolled from a single site." - Anonymous Online Contributor